Pharmacokinetic studies of 13-cis-retinoic acid in pediatric patients with neuroblastoma following bone marrow transplantation

Cancer Chemotherapy and Pharmacology

Volumn 39, Issue 1-2, 1996, Pages 34-41

  Khan, Anis A ^a,b   Villablanca, Judith G ^a   Reynolds, C Patrick ^a   Avramis, Vassilios I ^a  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

^b PALO ALTO MEDICAL FOUNDATION   (United States)

Author keywords

13 cis Retinoic acid; Bone marrow transplantation; Neuroblastoma; Pediatrics; Pharmacokinetics

Indexed keywords

4 OXOISOTRETINOIN; DRUG METABOLITE; RETINOIC ACID;

ARTICLE; BONE MARROW TRANSPLANTATION; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERCALCEMIA; ISOMERISM; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MODEL; NEUROBLASTOMA; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; SKIN TOXICITY;

ADMINISTRATION, ORAL; AREA UNDER CURVE; BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; ISOTRETINOIN; KERATOLYTIC AGENTS; MALE; NEUROBLASTOMA; SEX FACTORS; STEREOISOMERISM;

EID: 0029800569     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050535     Document Type: Article

References (35)

1. Sherman MI (1986) Retinoids and cell differentiation. CRC Press, Boca Raton
2. Sporn MB, Roberts AB, Goodman DS (eds) (1984) The retinoids, vols 1 and 2. Academic Press, New York
3. Lotan R (1980) Effects of vitamin A and its analogs (retinoids) on normal and neoplastic cells. Biochim Biophys Acta 605:33-91
4. Peck GL, Yoder FW (1976) Treatment of lamellar ichthyosis and other keratinizing dermatoses with an oral synthetic retinoid. Lancet 2:1172-1174
5. Hong WK, Lippman SM, Itri LM, Karp DD, Lee JS, Byers RM, Schantz SP, Kramer AM, Lotan R, Peters LJ, Demery IW, Brown BW Goepfert H (1990) Prevention of second primary tumors with isotretinoin in squamous cell carcinoma of the head and neck. N Engl J Med 323:795-801
6. Seeger RC, Reynolds CP (1991) Treatment of high-risk solid tumors of childhood with intensive therapy and autologous bone marrow transplantation. Pediatr Clin North Am 38:393-424
7. Villablanca JG, Khan AA, Avramis VI, Seeger RC, Matthay KK, Ramsay NKC, Reynolds CP (1995) Phase I trial of 13-cis-retinoic acid in children with neuroblastoma following bone marrow transplantation. J Clin Oncol 13:894-901
8. Reynolds CP, Maples J (1985) Modulation of cell surface antigens accompanies morphological differentiation of human neuroblastoma cell lines. Prog Clin Biol Res 175:13-37
9. Reynolds CP, Schindler P, Jones D, Gentile J, Proffitt R, Einhorn P (1994) Comparison of 13-cis-retinoic acid to trans-retinoic acid using human neuroblastoma cell lines. Adv Neuroblastoma Res 4:237-244
10. Sidell N, Altman A, Haussler MR, Seeger RC (1983) Effects of retinoic acid (RA) on the growth and phenotypic expression of several human neuroblastoma cell lines. Exp Cell Res 148:21-30
11. Thiele CJ, Reynolds CP, Israel MA (1985) Decreased expression of N-myc precedes retinoic acid-induced morphological differentiation of human neuroblastoma. Nature 313:404-406
12. Finklestein JZ, Krailo MD, Lenarsky C, Ladisch S, Blair GK, Reynolds CP, Sitarz AL, Hammond GD (1992) 13-cis-retinoic acid (NSC 122758) in the treatment of children with metastatic neuroblastoma unresponsive to conventional chemotherapy: report from the Childrens Cancer Study Group. Med Pediatr Oncol 20:307-311
13. Reynolds CP, Kane DJ, Einhorn PA, Matthay KK, Crouse VL, Wilbur JR, Shurin SB, Seeger RC (1991) Response of neuroblastoma to retinoic acid in vitro and in vivo. Prog Clin Biol res 366:203-211
14. Colburn WA, Vane FM, Shorter HJ (1983) Pharmacokinetics of Isotretinoin and its major blood metabolite following a single oral dose to man. Eur J Clin Pharmacol 24:689-694
15. Li C, Reynolds CP (1994) Expression of retinoic acid receptors alpha, beta, and gamma in human neuroblastoma cell lines. In: Evans AE, Biedler JL, Brodeur GM et al (eds) Advances in neuroblastoma research, vol 4. Wiley, New York, pp 221-227
16. Bugge CJL, Rodriguez LC, Vane FM (1985) Determination of isotretinoin or etretinate and their major metabolites in human blood by reversed-phase high-performance liquid chromatography. J Pharm Biomed Anal 3:269-277
17. Lucek RW, Colburn WA (1985) Clinical pharmacokinetics of the retinoids. Clin Pharmacokinet 10:38-62
18. Brazzell RK, Vane FM, Ehmann CW, Colburn WA (1983) Pharmacokinetics of isotretinoin during repetitive dosing to patients. Eur J Clin Pharmacol 24:695-702
19. Goodman GE, Einspahr JG, Alberts DS, Davis TP, Leigh SA, Chen HSG, Meyskens FL (1982) Pharmacokinetics of 13-cis-retinoic acid in patients with advanced cancer. Cancer Res 42:2087-2091
20. Villablanca JG, Khan AA, Avramis VI, Reynolds CP (1993) Hypercalcemia: a dose limiting toxicity associated with 13-cis-retinoic acid. Am J Pediatr Hematol Oncol 15(4):410-415
21. Hultin TA, Mehta RG, Moon RC (1985) Simple high-performance liquid chromatographic method for the separation of retinoids including N-(4-hydroxyphenyl)-all-trans-retinamide. J Chromatogr 341:187-192
22. Wyss R (1990) Chromatography of retinoids. J Chromatogr 531:481-508
23. Kerr IG, Lippman ME, Jenkins J, Myers CE (1982) Pharmacology of 13-cis-retinoic acid in humans. Cancer Res 42:2069-2073
24. Frolik CA, Tavela TE, Peck GL, Sporn MB (1978) High-pressure liquid chromatographic determination of 13-cis-retinoic acid and all-trans-retinoic acid in human serum. Anal Biochem 86:743-750
25. Vane FM, Stoltenborg JK, Bugge CJL (1982) Determination of 13-cis-retinoic acid and its major metabolite, 4-oxo-13-cis-retinoic acid, in human blood by reversed phase high performance liquid chromatography. J Chromatogr 227:471-484
26. Puglisi CV, De Silva JAF (1978) Determination of retinoic acid (13-cis- and all-trans) and aromatic retinoic acid analogs possessing anti-tumor activity, in biological fluids by high-performance liquid chromatography. J Chromatogr 152:421-430
27. D'Argenio DZ, Schumitzky A (1992) ADAPT II, mathematical software for pharmacokinetic/pharmacodynamic systems analysis: user's guide. Biomedical Simulations Resource, University of Southern California
28. Smith MA, Adamson PC, Balis FM, Feusner J, Aronson L, Murphy RF, Horowitz ME, Reaman G, Hammond DG, Fenton RM, Connaghan GD, Hittleman WN, Poplack DG (1992) Phase I and pharmacokinetic evaluation of all-trans-retinoic acid in pediatric patients with cancer. J Clin Oncol 10:1666-1673
29. Lee JS, Newman RA, Lippman SM et al (1993) Phase I evaluation of all-trans-retinoic acid in adults with solid tumor. J Clin Oncol 11:959-966
30. Muindi J, Frankel SR, Miller W Jr et al (1992) Continuous treatment with all-trans-retinoic acid causes a progressive reduction in plasma drug concentrations: implications for relapse and retinoid "resistance", in patients with acute promyelocytic leukemia. Blood 79:299-303
31. Gibaldi M, Perrier D (1982) Pharmacokinetics, 2nd edn. Marcel Dekker, New York Basel
32. Khoo KC, Reik D, Colburn WA (1982) Pharmacokinetics of isotretinoin following a single oral dose. J Clin Pharmacol 22:395-402
33. Adamson PC, Pilot HC, Balis FM, Rubin J, Murphy RF, Poplack DG (1993) Variability in the oral bioavailability of all-trans-retinoic acid. J Natl Cancer Inst 85:993-996
34. Meyskens F, Goodman G, Alberts D (1987) 13-cis-retinoic acid: pharmacology, toxicology, and clinical applications for the prevention and treatment of human cancer. Crit Rev Oncol Hematol 3:75-101
35. Khan AA, Reynolds CP, Avramis VI (1994) Pharmacologic studies of 13-cis retinoic acid (cis-RA) in athymic mice with human neuroblastoma (NB) xenografts (abstract). Proc Am Assoc Cancer Res 35:424